Medicine-taking behavior: Implications of suboptimal compliance in Parkinson's disease

Management of Parkinson's disease (PD) depends primarily on oral medication. There are several drug classes and multiple doses and formulations, which make optimizing therapy complex. Variable drug absorption and the short half‐life of most antiparkinson treatments, especially levodopa, are a m...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders 2005-11, Vol.20 (11), p.1397-1404
Main Authors: Grosset, Katherine A., Reid, John L., Grosset, Donald G.
Format: Article
Language:English
Subjects:
Antiparkinson Agents - economics
Antiparkinson Agents - therapeutic use
Biological and medical sciences
clinical consequences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
drug compliance
Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy
Health Behavior
Humans
Medical sciences
Nervous system (semeiology, syndromes)
Neurology
Parkinson Disease - drug therapy
Parkinson Disease - economics
Parkinson Disease - psychology
Parkinson's disease
Patient Compliance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Management of Parkinson's disease (PD) depends primarily on oral medication. There are several drug classes and multiple doses and formulations, which make optimizing therapy complex. Variable drug absorption and the short half‐life of most antiparkinson treatments, especially levodopa, are a main focus in understanding complications and have encouraged alternative delivery systems to limit fluctuation and dyskinesia at later stages. Comparatively little attention is paid to the way patients take their oral medication. Variable medicine‐taking behavior can affect the clinician's understanding of the diagnosis and rate of progression, and further prescription of PD medication. Medicine overuse in later stage PD is well documented and causes psychiatric disturbance and increases motor complications, but evidence of undertreatment and erratic intake is emerging, which is likely to affect motor control and quality of life adversely. Methods of quantifying compliance are compared for accuracy and limitations. Understanding medicine‐taking behavior is a first step in optimizing therapy and requires consideration of a patient's personal beliefs about their medicines. Although the benefits of regularizing oral medicine‐taking in a practical, achievable way in PD remain untested, such an approach might prolong and smooth the benefits of oral medication and is worthy of further research. © 2005 Movement Disorder Society
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.20525